Published in J Biomed Biotechnol on June 13, 2011
IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med (2013) 1.00
Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro. Blood (2013) 0.98
Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates. J Immunol (2012) 0.95
Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett (2015) 0.91
Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference? PLoS One (2013) 0.86
A potential novel spontaneous preterm birth gene, AR, identified by linkage and association analysis of X chromosomal markers. PLoS One (2012) 0.85
IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res (2015) 0.83
Monocytes play an IL-12-dependent crucial role in driving cord blood NK cells to produce IFN-g in response to Trypanosoma cruzi. PLoS Negl Trop Dis (2013) 0.82
The role of natural killer cells in pulmonary immunosurveillance. Front Biosci (Schol Ed) (2013) 0.81
Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells. J Immunother Cancer (2014) 0.79
Functional NK cell repertoires are maintained through IL-2Rα and Fas ligand. J Immunol (2014) 0.79
The Roles of IL-2, IL-7, and IL15 Ligands in B Cells Development from Cord Blood Mononuclear Cells. Iran J Ped Hematol Oncol (2015) 0.78
Influence of Sex on Basal and Dickkopf-1 Regulated Gene Expression in the Bovine Morula. PLoS One (2015) 0.77
Essential role of NK cells in IgG therapy for experimental autoimmune encephalomyelitis. PLoS One (2013) 0.76
CD300c is uniquely expressed on CD56(bright) Natural Killer Cells and differs from CD300a upon ligand recognition. Sci Rep (2016) 0.76
Active immunization with human interleukin-15 induces neutralizing antibodies in non-human primates. BMC Immunol (2016) 0.76
KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance. Oncoimmunology (2014) 0.75
Natural killer cells in healthy and diseased subjects. J Biomed Biotechnol (2011) 0.75
IL2rg Cytokines Enhance Umbilical Cord Blood CD34+ Cells Differentiation to T Cells. Adv Pharm Bull (2015) 0.75
T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol (1978) 28.92
A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol (2005) 11.48
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med (2000) 9.78
Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol (1999) 8.98
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med (1994) 8.97
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity (1998) 8.29
A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature (2008) 8.22
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med (2005) 7.87
Human natural killer cells. Blood (2008) 7.37
Structure and expression of a cloned cDNA for human interleukin-2. Nature (1983) 7.04
Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity (1995) 6.91
Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell (1993) 6.83
Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science (1994) 6.65
T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol (2006) 6.23
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol (2006) 6.22
IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity (2002) 6.10
RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol (2008) 5.91
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57
Natural cell-mediated immunity. Adv Cancer Res (1978) 5.53
Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity (2007) 5.50
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell (2002) 5.44
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood (2001) 5.23
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med (1994) 5.20
Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A (1995) 5.06
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 4.92
Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol (2008) 4.90
Cloning of the gamma chain of the human IL-2 receptor. Science (1992) 4.50
Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science (1993) 4.39
Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet (1998) 4.32
Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A (2009) 3.74
A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol (2006) 3.74
Janus kinases in immune cell signaling. Immunol Rev (2009) 3.60
Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J (1995) 3.59
Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol (1995) 3.34
Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity (2010) 3.27
Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol (1999) 3.18
IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity (2002) 3.17
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity (2005) 3.14
Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J (2003) 3.06
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med (2008) 3.03
Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity (1998) 3.03
Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity (2009) 3.02
Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med (2001) 2.96
Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J Exp Med (1997) 2.91
Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity (2007) 2.91
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J Exp Med (2010) 2.87
In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood (2002) 2.85
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A (1994) 2.79
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med (1990) 2.79
NK cell and DC interactions. Trends Immunol (2004) 2.68
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J Exp Med (2003) 2.51
A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest (1997) 2.37
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol (2005) 2.35
Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc Natl Acad Sci U S A (2010) 2.35
IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med (2008) 2.33
What does it take to make a natural killer? Nat Rev Immunol (2003) 2.30
The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci U S A (1987) 2.22
IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood (2003) 2.20
Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood (2009) 2.18
Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev (2004) 2.18
Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A (2000) 2.16
T cell-independent interleukin 15Ralpha signals are required for bystander proliferation. J Exp Med (2001) 2.16
Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol (2009) 2.04
Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem (2005) 2.01
IL-21 induces the functional maturation of murine NK cells. J Immunol (2004) 2.00
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med (1983) 1.99
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97
Cellular sources and immune functions of interleukin-9. Nat Rev Immunol (2010) 1.92
Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J Biol Chem (1995) 1.90
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res (2004) 1.87
Human natural killer cell development and biology. Blood Rev (2005) 1.83
In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res (2003) 1.81
Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity (2009) 1.75
Natural killer-cell differentiation by myeloid progenitors. Blood (2010) 1.75
Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2010) 1.74
Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med (1990) 1.73
Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood (1999) 1.71
Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev (2006) 1.71
Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol (1995) 1.69
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res (2007) 1.66
Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett (2009) 1.64
The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J Immunol (1998) 1.60
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol (2008) 1.60
The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol (2003) 1.60
IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol (2004) 1.58
Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood (2010) 1.56
Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol (2004) 1.56
Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol (2002) 1.55
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res (2010) 1.51
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood (2010) 1.41
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol (2004) 1.58
Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood (2011) 1.43
Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem (2009) 1.41
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood (2006) 1.38
CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol (2007) 1.35
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32
The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res (2007) 1.25
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res (2004) 1.25
Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood (2005) 1.22
Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res (2008) 1.16
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood (2007) 1.12
In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment. Blood (2003) 1.12
Antimetastatic activity of a preventive cancer vaccine. Cancer Res (2007) 1.07
The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int J Cancer (2008) 1.07
Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol (2011) 1.07
Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst (2011) 1.05
Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets (2006) 1.03
Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle (2013) 1.03
Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One (2011) 1.02
Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. Nat Med (2002) 1.02
Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression. PLoS One (2012) 1.01
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res (2006) 1.01
Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol (2003) 0.98
An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease. Haematologica (2011) 0.97
CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol (2006) 0.97
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am J Pathol (2005) 0.97
Fibroblasts from human spleen regulate NK cell differentiation from blood CD34(+) progenitors via cell surface IL-15. J Immunol (2002) 0.97
Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. Sci Rep (2013) 0.96
Gliadin-mediated proliferation and innate immune activation in celiac disease are due to alterations in vesicular trafficking. PLoS One (2011) 0.96
IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer (2009) 0.96
Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice. Int J Cancer (2010) 0.95
Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody. J Cell Sci (2005) 0.94
Role of CXCL13-CXCR5 crosstalk between malignant neuroblastoma cells and Schwannian stromal cells in neuroblastic tumors. Mol Cancer Res (2011) 0.94
Caspase-8 gene expression in neuroblastoma. Ann N Y Acad Sci (2004) 0.93
CD40 on adult human airway epithelial cells: expression and proinflammatory effects. J Immunol (2004) 0.92
Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res (2005) 0.91
Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice. Mol Med (2010) 0.90
TLR ligands stimulation protects MSC from NK killing. Stem Cells (2014) 0.90
Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS One (2008) 0.90
Immunotherapeutic applications of IL-15. Immunotherapy (2012) 0.90
Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. Cancer Res (2009) 0.90
Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: relationship with Snail. Int J Oncol (2010) 0.89
Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha. Eur J Immunol (2002) 0.89
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One (2009) 0.89
Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer (2007) 0.89
New perspectives in glioma immunotherapy. Curr Pharm Des (2011) 0.89
Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. Int J Cancer (2008) 0.89
Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer (2012) 0.88
Role of IL-21 in immune-regulation and tumor immunotherapy. Cancer Immunol Immunother (2007) 0.88
Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB. Int Immunol (2005) 0.88
Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res (2007) 0.87
An interferon-sensitive response element is involved in constitutive caspase-8 gene expression in neuroblastoma cells. Int J Cancer (2007) 0.87
Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther (2005) 0.87
Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J Cell Physiol (2010) 0.87
Human renal cancer stem cells. Cancer Lett (2012) 0.87
Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int J Cancer (2002) 0.86
Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway. PLoS One (2012) 0.85
NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. Int Immunol (2009) 0.85
MR and iron magnetic nanoparticles. Imaging opportunities in preclinical and translational research. Tumori (2008) 0.85
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-gamma in promyelocytic cells. Int Immunol (2008) 0.84
Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. Exp Hematol (2010) 0.84
Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. Cytokine Growth Factor Rev (2012) 0.83
Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity. Cancer Immunol Immunother (2014) 0.82
Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse. Cell Oncol (2010) 0.82
IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. Eur J Immunol (2002) 0.82
Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood (2002) 0.81
Two-step in vivo tumor targeting by biotin-conjugated antibodies and superparamagnetic nanoparticles assessed by magnetic resonance imaging at 1.5 T. Mol Imaging Biol (2009) 0.81
Interferon-alpha triggers B cell effector 1 (Be1) commitment. PLoS One (2011) 0.81
Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother (2008) 0.81
A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. Oncogene (2004) 0.81
Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS One (2011) 0.81
Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin Cancer Res (2005) 0.80
The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment. Clin Cancer Res (2013) 0.80
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion. Pigment Cell Melanoma Res (2014) 0.80
Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. Int J Cancer (2011) 0.80